Lyka Labs LimitedQuarter Ended 30th Sept, 2026 Results & Financial Update
Lyka Labs Limited: Quarter Ended 30th Sept, 2026 consolidated results and company financials – revenue ₹44.20 Cr, PAT ₹1.27 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Lyka Labs price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Lyka Labs Quarter Ended 30th Sept, 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Lyka Labs Limited reported consolidated revenue from operations of INR 44.20 crore for the quarter ended September 30, 2026, representing an increase compared to INR 36.66 crore in the corresponding period of the previous year and INR 42.31 crore in the preceding quarter ended June 30, 2026.
Total consolidated income for the reporting quarter stood at INR 44.82 crore, supported by other income of INR 0.62 crore. Total expenses for the quarter aggregated to INR 43.75 crore, reflecting adjustments across material consumption, employee expenses, and operational overheads.
The consolidated profit before tax for Q2 FY27 was recorded at INR 1.07 crore, compared to a loss before tax of INR 4.38 crore in the corresponding quarter of the previous year, demonstrating a positive turnaround on a year-on-year basis.
Consolidated net profit after tax for the quarter stood at INR 1.27 crore, compared to a net loss of INR 3.21 crore reported in the same quarter last year. On a sequential basis, net profit moderated from INR 2.05 crore recorded in the quarter ended June 30, 2026.
Basic and diluted earnings per share for the quarter were recorded at INR 0.36, compared to INR (0.94) in the corresponding quarter of the previous year and INR 0.57 in the preceding quarter.
The company continues to operate within a single primary business segment, which is pharmaceuticals, ensuring strategic focus on core therapeutic formulations and manufacturing efficiencies.
01 · Business model
What does Lyka Labs do?
Lyka Labs Limited operates in the pharmaceuticals sector, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical formulations. The company manages its operations through its registered and corporate footprints primarily centered in Mumbai and Ankleshwar.
The primary revenue engine is derived from pharmaceutical operations involving active pharmaceutical ingredients and finished dosage formulations, catering to diverse medical needs. The business model integrates in-house manufacturing capabilities with a structured supply chain spanning domestic and international markets.
The corporate structure includes subsidiaries such as Lyka BDR International Limited, contributing to the consolidated operational scope. The company engages in continuous process improvements and quality control to sustain its product portfolio across therapeutic segments.
02 · Historical context
What shaped the business before this quarter
The Hon'ble National Company Law Tribunal, Ahmedabad Bench, sanctioned a Scheme of Amalgamation for the merger of Lyka Export Limited into Lyka Labs Limited, with accounting treatment and restated figures effected under IND AS 103 from the required transition date.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter Ended 30th Sept, 2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹44.20 Cr | ₹36.66 Cr | ₹42.31 Cr |
| Total income | ₹44.82 Cr | ₹37.75 Cr | ₹42.73 Cr |
| EBITDA | ₹4.14 Cr | ₹-1.45 Cr | — |
| Profit before tax | ₹1.07 Cr | ₹-4.38 Cr | ₹1.95 Cr |
| Profit after tax | ₹1.27 Cr | ₹-3.21 Cr | ₹2.05 Cr |
| EPS | ₹0.36 | ₹-0.94 | ₹0.57 |
| EBITDA margin | 9.37% | -3.95% | — |
Financial interpretation
What the reported numbers mean
Profit after tax represented 2.9% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 2.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.62 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations grew to INR 44.20 crore during the quarter, underpinned by steady demand across pharmaceutical product lines and formulations.
Total income reached INR 44.82 crore, bolstered by INR 0.62 crore in other income streams during the quarter.
What drove margins
Material consumption costs stood at INR 13.58 crore alongside stock-in-trade purchases of INR 4.65 crore, offset by inventory adjustments of finished goods and work-in-progress.
Employee benefit expenses were recorded at INR 12.58 crore, while other expenses aggregated to INR 10.20 crore for the quarter.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates entirely within one primary business segment designated as pharmaceuticals.
06 · Reported developments
What changed operationally
The company transitioned from a pre-tax loss of INR 4.38 crore in Q2 FY26 to a positive pre-tax profit of INR 1.07 crore in Q2 FY27.
07 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
For the half year ended September 30, 2026, net cash generated from operating activities on a standalone basis stood at INR 1,265.64 lakh after accounting for working capital changes and tax payments.
Standalone cash used in investing activities for the half year ended September 30, 2026, amounted to INR 623.10 lakh, primarily driven by fixed asset purchases.
Capital allocation & funding
Finance costs for the quarter were recorded at INR 1.02 crore, reflecting ongoing debt servicing commitments across non-current and current borrowing facilities.
08 · Beyond the numbers
What changed beyond the numbers
Reported update
Director Re-appointment
The Board approved the re-appointment of Mr. Neeraj Golas as an Independent Director for a period of three consecutive years commencing January 16, 2027, subject to shareholder approval via postal ballot.
09 · Previous-quarter changes
What changed since the previous quarter
Consolidated net profit after tax moderated from INR 2.05 crore in Q1 FY27 to INR 1.27 crore in Q2 FY27.
10 · Key Q&A
The quarter, answered directly
What does Lyka Labs do?
Lyka Labs Limited operates in the pharmaceuticals sector, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical formulations. The company manages its operations through its registered and corporate footprints primarily centered in Mumbai and Ankleshwar.
What is the clearest takeaway from Quarter Ended 30th Sept, 2026?
Lyka Labs Limited reported consolidated revenue from operations of INR 44.20 crore for the quarter ended September 30, 2026, representing an increase compared to INR 36.66 crore in the corresponding period of the previous year and INR 42.31 crore in the preceding quarter ended June 30, 2026.
What drove revenue or demand?
Revenue from operations grew to INR 44.20 crore during the quarter, underpinned by steady demand across pharmaceutical product lines and formulations.
What mattered most for margins or profitability?
Material consumption costs stood at INR 13.58 crore alongside stock-in-trade purchases of INR 4.65 crore, offset by inventory adjustments of finished goods and work-in-progress.
What changed operationally beyond the headline numbers?
The Board approved the re-appointment of Mr. Neeraj Golas as an Independent Director for a period of three consecutive years commencing January 16, 2027, subject to shareholder approval via postal ballot.
What should the next disclosure help confirm?
Shareholder voting outcomes regarding the re-appointment of independent directors via postal ballot.
11 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario operating profit₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
12 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Postal Ballot Resolution: Shareholder voting outcomes regarding the re-appointment of independent directors via postal ballot.
- 02
Subsequent Financial Performance: Execution of pharmaceutical manufacturing orders and sequential margin trends in upcoming quarters.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.